Probiotic interventions in peritoneal dialysis: A review of underlying mechanisms and therapeutic potentials.

Natalia Stepanova
{"title":"Probiotic interventions in peritoneal dialysis: A review of underlying mechanisms and therapeutic potentials.","authors":"Natalia Stepanova","doi":"10.5527/wjn.v13.i4.98719","DOIUrl":null,"url":null,"abstract":"<p><p>Peritoneal dialysis (PD) is a commonly used modality for kidney replacement therapy for patients with end-stage kidney disease (ESKD). PD offers many benefits, including home-based care, greater flexibility, and preservation of residual kidney function compared to in-center hemodialysis. Nonetheless, patients undergoing PD often face significant challenges, including systemic inflammation, PD-related peritonitis, metabolic disorders, and cardiovascular issues that can negatively affect their quality of life and treatment outcomes. Recent studies have demonstrated the crucial role of the gut microbiome in overall health and treatment results, supporting the hypothesis that probiotics may bring potential benefits to the general population of ESKD patients. However, specific data on probiotic use in PD patients are limited. This opinion review aims to summarize the current knowledge on the relationship between PD and the gut microbiome and offers a novel perspective by specifically exploring how probiotic interventions could improve the outcomes of PD treatment. The review also outlines some clinical data supporting the effectiveness of probiotics in patients undergoing PD and considers the difficulties and restrictions in their application. Based on the current knowledge gaps, this study seeks to explore future research directions and their implications for clinical practice.</p>","PeriodicalId":94272,"journal":{"name":"World journal of nephrology","volume":"13 4","pages":"98719"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572655/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5527/wjn.v13.i4.98719","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Peritoneal dialysis (PD) is a commonly used modality for kidney replacement therapy for patients with end-stage kidney disease (ESKD). PD offers many benefits, including home-based care, greater flexibility, and preservation of residual kidney function compared to in-center hemodialysis. Nonetheless, patients undergoing PD often face significant challenges, including systemic inflammation, PD-related peritonitis, metabolic disorders, and cardiovascular issues that can negatively affect their quality of life and treatment outcomes. Recent studies have demonstrated the crucial role of the gut microbiome in overall health and treatment results, supporting the hypothesis that probiotics may bring potential benefits to the general population of ESKD patients. However, specific data on probiotic use in PD patients are limited. This opinion review aims to summarize the current knowledge on the relationship between PD and the gut microbiome and offers a novel perspective by specifically exploring how probiotic interventions could improve the outcomes of PD treatment. The review also outlines some clinical data supporting the effectiveness of probiotics in patients undergoing PD and considers the difficulties and restrictions in their application. Based on the current knowledge gaps, this study seeks to explore future research directions and their implications for clinical practice.

益生菌干预腹膜透析:潜在的机制和治疗潜力的回顾。
腹膜透析(PD)是终末期肾病(ESKD)患者肾脏替代治疗的常用方式。与中心血液透析相比,PD有许多好处,包括家庭护理、更大的灵活性和保留残余肾功能。尽管如此,PD患者经常面临重大挑战,包括全身性炎症、PD相关腹膜炎、代谢紊乱和心血管问题,这些都会对患者的生活质量和治疗结果产生负面影响。最近的研究表明,肠道微生物组在整体健康和治疗结果中起着至关重要的作用,支持了益生菌可能为ESKD患者的一般人群带来潜在益处的假设。然而,PD患者使用益生菌的具体数据有限。本综述旨在总结目前关于PD与肠道微生物组之间关系的知识,并通过具体探讨益生菌干预如何改善PD治疗结果提供了一个新的视角。综述还概述了一些支持益生菌对PD患者有效性的临床数据,并考虑了其应用的困难和限制。基于目前的知识缺口,本研究试图探索未来的研究方向及其对临床实践的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.40
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信